Shirley Clayton
Angel Investor
Shirley Clayton is a seed investor focused on Life Science and Biotechnology. Prior to joining the board in February 2007, Ms. Clayton retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. As VP and Treasurer at Genentech, Inc., the first biopharmaceutical company, Ms. Clayton was actively involved in the early financing of the biotechnology industry. Prior to her role atAbmaxis, she co-founded Raven Biotechnologies, a cell biology company developing monoclonal antibody products, and served as its President and Chief Financial Officer. During her 25 years as an executive in the life science industry, Ms. Clayton was Chief Financial Officer, President or Chief Executive Officer in several companies including Protein Design Labs, now PDL BioPharma, Inc.; Cygnus, Inc., a drug delivery company; and CBYON, a medical technology company sold to GE Medical Systems. She is a member of the Board and Audit committee of Metro Bancorp and a member of the Board of Metro United Bank and Chairman of its Credit committee. Ms. Clayton received a BS in Chemistry from Smith College and an MBA from the Stanford University Graduate School of Business.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Shirley Clayton invests in
Stages Shirley Clayton invests in
Countries Shirley Clayton invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. | $438.1K / Seed / Feb 17, 2016 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shirley Clayton invest in?
Shirley Clayton invests primarily in Life Science and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shirley Clayton?
Public channels for Shirley Clayton include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shirley Clayton last invest?
The most recent investment recorded for Shirley Clayton closed in Feb 2016. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
